Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment

StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This study evaluates the effects of Ginkgo biloba on blood biomarkers related to Alzheimer's disease in patients with mild cognitive impairment. Participants will be randomly assigned to receive either Ginkgo biloba or a placebo for 6 months. Changes in blood biomarkers, including p-tau217 and neurofilament light (NfL), as well as cognitive function, will be assessed to determine whether Ginkgo biloba may influence disease-related biological processes.
Trial Details
NCT Number NCT07579689
Lead Sponsor Hanyang University
Collaborators: SK Chemicals
Conditions
(from sponsor)		 Mild Cognitive Impairment, Alzheimer's Disease
Related terms Alzheimer Disease, Cognitive Dysfunction
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov